Australian trial of behavioural activation for people with schizophrenia experiencing negative symptoms: a feasibility randomised controlled trial protocol.

Autor:	Muyambi K; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia kuda.muyambi@unisa.edu.au., Walsh S; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia., Dettwiller P; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia., Tan KL; UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia., Dennis S; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia.; Rural and Remote Mental Health Service, Barossa Hills Fleurieu Local Health Network, Whyalla, South Australia, Australia., Bressington D; Charles Darwin University College of Nursing & Midwifery, Casuarina, Odisha, Australia., Gray RJ; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia.; School of Nursing, La Trobe University, Bundoora, Victoria, Australia., McCall A; Flinders and Upper North Local Health Network, Whyalla, South Australia, Australia., Jones M; Department of Rural Health, University of South Australia, Whyalla Norrie, South Australia, Australia.; School of Nursing, La Trobe University, Bundoora, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 May 06; Vol. 14 (5), pp. e080245. Date of Electronic Publication: 2024 May 06.
DOI:	10.1136/bmjopen-2023-080245
Abstrakt:	Introduction: Negative symptoms are frequently experienced by people with schizophrenia. People with negative symptoms often have impaired social functioning and reduced quality of life. There is some evidence that cognitive-behavioural therapy results in a modest reduction in negative symptoms. Behavioural activation may be an effective alternative treatment for negative symptoms.The study aims to examine the feasibility and acceptability of implementing a behavioural activation trial delivered in three community mental health services in South Australia to support adult consumers experiencing negative symptoms of schizophrenia. Method and Analysis: This randomised controlled study will recruit a total of 60 consumers aged 18 years or above with mild-moderate negative symptoms of schizophrenia. The consumers will be randomly allocated to receive behavioural activation plus usual mental healthcare or usual mental healthcare alone. The intervention group will receive twelve 30 min sessions of behavioural activation, which will be delivered twice weekly over 6 weeks. In addition, we aim to recruit nine mental health workers from the three rural mental health services who will complete a 10-week online training programme in behavioural activation. Changes in negative symptoms of schizophrenia and depressive symptoms will be assessed at three time points: (a) at baseline, at 6 weeks and 3 month follow-ups. Changes in health-related quality of life (Short Form F36; secondary outcome) will be assessed at two time points: (a) at baseline and (b) immediately at postintervention after 6 weeks. At the end of the trial, interviews will be conducted with purposively selected mental health workers and consumers. Descriptive statistics and thematic analysis will be used to assess feasibility and acceptability. Ethics and Dissemination: The findings from our feasibility study will inform the design of a fully powered randomised controlled trial to test the effectiveness of behavioural activation as a treatment for negative symptoms in schizophrenia. The study protocol was approved by the Central Adelaide Local Health Network Human Research Ethics Committee. The findings from this study will be disseminated through peer-reviewed scientific journals and conferences. Trial Registration Number: ACTRN12623000348651p. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu